Table 1.
Grading of Recommendations Assessment, Development and Evaluation (GRADE) evidence profile for population, intervention, comparison, outcome 16: Sotrovimab for mild or moderate coronavirus disease 2019a
| People: Patients with mild-to-moderate COVID-19 Settings: Ambulatory patients Intervention: Sotrovimab at 500 mg administered intravenously Comparison: No treatment | |||||
|---|---|---|---|---|---|
| Outcomes | Absolute effect |
Relative effect (95% CI) | Number of studies | Certainty of the evidence (GRADE) | |
| With sotrovimab | Without sotrovimab | ||||
| All-cause mortality (within 29 d from treatment) | 0/291 (0) | 1/292 (0.3%) | RR: 0.33 (0.01–8.18) | 1 [20] (583 patients) | ⊕⊕⊖⊖ Low (due to very serious imprecision) |
| Difference: 3 fewer per 1000 (95% CI: −10 to 3) | |||||
| Hospitalization (within 29 d from treatment) | 3/291 (1.0%) | 21/292 (7.2%) | RR: 0.14 (0.04–0.48) | 1 [20] (583 patients) | ⊕⊕⊕⊖ Moderate (due to serious imprecision) |
| Difference: 62 fewer per 1000 (95% CI: −69 to −37) | |||||
| Serious adverse events (end of follow-up) | 7/430 (1.6%) | 26/438 (5.9%) | RR: 0.27 (0.12–0.63) | 1 [20] (5531 patients) | ⊕⊕⊕⊖ Moderate (due to serious imprecision) |
| Difference: 58 fewer per 1000 (95% CI: −64 to −36) | |||||
COVID-19, coronavirus disease 2019; GRADE, Grading of Recommendations Assessment, Development and Evaluation; RR, risk ratio.
aEvidence adopted: Infectious Disease Society of America guidelines available at https://www.idsociety.org/practice-guideline/COVID-19-guideline-treatment-and-management/. Evidence search date: 1–30 January 2022.